The Delta-8 Controversy

THC presents itself as two different isomers, delta-9-tetrahydrocannabinol and delta-8-tetrahydrocannabinol. Delta-8 is essentially an analogue of Delta-9. It works in the same way in that it is a partial agonist of the CB1 and CB2 receptors and has a particularly high binding affinity with the CB1 receptor.

There are claims that Delta-8 is less psychoactive than Delta-9 but this has not yet been backed up with scientific evidence.

The only difference between Delta-8 and Delta-9 is where the double bond is located on the chain of atoms. With Delta 8 the double bond is on the eighth carbon atom in the molecular structure, with Delta 9 the double bond is located on the ninth.

THC-V (Varient)

Another homologue of THC is THC-V. Although a variant of THC having a propyl (3-carbon) side chain instead of a pentyl (5-carbon) group on the molecule, it produces very different effects.

THC-V increases satiety and up-regulates energy metabolism, making it a clinically useful remedy for weight loss and management of obesity and type 2 diabetic patients.

The distinctions between THC-V and THC in terms of glycemic control, glucose metabolism, and energy regulation have been demonstrated in previous studies.

The effect of THC-V on dyslipidemia and glycemic control in type 2 diabetics has shown reduced fasting plasma glucose concentration when compared to a placebo group.

THC-V has the ability to provide neuroprotection, appetite suppression, glycemic control, and mitigation of side effects, therefore, making it a potential priority candidate for the development of clinically useful therapies in the future.